ВОЗМОЖНОСТИ ПРИМЕНЕНИЯ МЕТОДА ФЛУОРЕСЦЕНТНОЙ IN SITU ГИБРИДИЗАЦИИ (FISH) В ДИАГНОСТИКЕ РАКА МОЧЕВОГО ПУЗЫРЯ И ЕГО РЕЦИДИВОВ
https://doi.org/10.17650/1726-9776-2011-7-4-90-95
Аннотация
Флуоресцентная in situ гибридизация (FISH) — современный метод выявления в хромосомах специфических генетических нарушений, характерных для рака мочевого пузыря (РМП). Данный метод можно использовать для диагностики РМП, проведения динамического наблюдения за больными после хирургического лечения, оценки эффективности адъювантной терапии у этих больных, а также для прогнозирования развития рецидива заболевания.
Об авторах
В. Б. Матвеев
Отделение урологии ФГБУ РОНЦ им. Н.Н. Блохина РАМН
Россия
Россия
А. И. Карселадзе
Отделение патологоанатомии ФГБУ РОНЦ им. Н.Н. Блохина РАМН
Россия
Россия
А. П. Казарян
15-е урологическое отделение ГКБ № 7, Москва
Россия
Россия
А. В. Хачатурян
Отделение урологии ФГБУ РОНЦ им. Н.Н. Блохина РАМН
Россия
Россия
Б. Ш. Камолов
Отделение урологии ФГБУ РОНЦ им. Н.Н. Блохина РАМН
Россия
Россия
О. В. Гигиадзе
15-е урологическое отделение ГКБ № 7, Москва
Россия
Россия
С. А. Калинин
Отделение урологии ФГБУ РОНЦ им. Н.Н. Блохина РАМН
Россия
Россия
Список литературы
1. Halling K.C., Kipp B.R. Fluorescence in situ hybridization in diagnostic cytology. Hum Pathol 2007;38:1137–44.
2. Halling K.C., Kipp B.R. Adv Bladder Cancer Detection Using FISH (UroVysion Assay). Anat Pathol 2008;15:279−86.
3. Kipp B.R., Tanasescu M., Else T.A. et al. Quantitative fluorescence in situ hybridization and its ability to predict bladder cancer recurrence and progression to muscle-invasive bladder cancer. J Mol Diagn 2009;11(2):148−54.
4. Richter J., Jiang F., Gorog J.P. et al. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 1997;57: 2860–4.
5. Fadl-Elmula I., Gorunova L., Mandahl N. et al. Karyotypic characterization of urinary bladder transitional cell carcinomas. Genes Chromosomes Cancer 2000;29:256–65.
6. Sarosdy M.F., Schellhammer P., Bokinsky G. et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002;168:1950–4.
7. Клиническая онкоурология. Под ред. Б.П. Матвеева. М.: Вердана, 2003. 717 с.
8. Wang M.R., Perissel B., Taillandier J. et al. Nonrandom changes of chromosome 10 in bladder cancer. Detection by FISH to interphase nuclei. Cancer Genet Cytogenet 1994;73(1):8−10.
9. Cajulis R.S., Haines G.K . 3rd, Frias-Hidvegi D. et al. Cytology, flow cytometry, image analysis, and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washes: a comparative study. Diagn Cytopathol 1995;13(3):214−24.
10. Pycha A., Mian C., Haitel A. et al. Fluorescence in situ hybridization identifies more aggressive types of primarily noninvasive (stage pTa) bladder cancer. J Urol 1997;157:2116–9.
11. Zhang F.F., Arber D.A., Wilson T.G. et al. Toward the validation of aneusomy detection by fluorescence in situ hybridization in bladder cancer: comparative analysis with cytology, cytogenetics, and clinical features predicts recurrence and defines clinical testing limitations. Clin Cancer Res 1997;3:2317–28.
12. Reeder J.E., O'Connell M.J., Yang Z. et al. DNA cytometry and chromosome 9 aberrations by fluorescence in situ hybridization of irrigation specimens from bladder cancer patients. Urology 1998;51(5A Suppl):58−61.
13. Marano A., Pan Y., Li C. et al. Chromosomal numerical aberrations detected by fluorescence in situ hybridization on bladder washings from patients with bladder cancer. Eur Urol 2000;37(3):358−65.
14. Stamouli M.I., Panani A.D., Ferti A.D. et al. Detection of genetic alterations in primary bladder carcinoma with dual-color and multiplex fluorescence in situ hybridization. Cancer Genet Cytogenet 2004;149(2):107−13.
15. Kiemeney L.A., Schoenberg M. Familial transitional cell carcinoma. J Urol 1996;156(3):867−72.
16. Sandberg A.A., Berger C.S. Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of bladder cancer. J Urol 199;151(3):545−60.
17. Pycha A., Mian C., Posch B. et al. Numerical chromosomal aberrations in muscle invasive squamous cell and transitional cell cancer of the urinary bladder: an alternative to classic prognostic indicators? Urology 1999;53(5):1005−10.
18. Sokolova I.A., Halling K.C., Jenkins R.B. et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000; 2:116–23.
19. Cajulis R.S., Haines G.K. III, Frias-Hidvegi D. et al. Interphase cytogenetics as an adjunct in the cytodiagnosis of urinary bladder carcinoma. A comparative study of cytology, flow cytometry and interphase cytogenetics in bladder washes. Anal Quant Cytol Histol 1994;16:1–10.
20. Bubendorf L., Grilli B. UroVysion multiprobe FISH in urinary cytology. Methods Mol Med 2004;97:117–31.
21. http://www.nikon-microscope.ru/fish_dna.htm
22. Halling K.C. Vysis UroVysion for the detection of urothelial carcinoma. Expert Rev Mol Diagn 2003;3:507–19.
23. Bubendorf L., Grilli B., Sauter G. et al. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 2001;116:79–86.
24. Halling K.C., King W., Sokolova I.A. et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 2002;167:2001–6.
25. Halling K.C., King W., Sokolova I.A. et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000;164(5):1768−75.
26. Halling K.C., Kipp B.R. Fluorescence in situ hybridisation for the detection of bladder cancer. Eur Ren Genitourinary Dis 2006; 2:51–4.
27. Laudadio J., Keane T.E., Reeves H.M. et al. Fluorescence in situ hybridization for detecting transitional cell carcinoma: Implications for clinical practice. Urologic Oncology: Seminars and Original Investigations 2006;24(3):270−1.
28. Gudjуnsson S., Isfoss B.L., Hansson K. et al. The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer. Eur Urol 2008;54(2):402−8.
29. Башкатов С.В. Прогностическое значение молекулярно-цитогенетических и молекулярно-биологических нарушений в клетках поверхностной уротелиальной карциномы. Автореф. дис. … канд. мед. наук, 2008, 20 с.
30. Van Rhijn B.W., van der Poel H.G., van der Kwast T.H. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005;47(6):736−48.
31. May M., Hakenberg O.W., Gunia S. et al. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice. Urology 2007; 70(3) 449−53.
32. Skacel M., Fahmy M., Brainard J.A. et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003; 169:2101–5.
33. Yoder B.J., Skacel M., Hedgepeth R. et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 2007;127:295–301.
34. Kipp B.R., Karnes R.J., Brankley S.M. et al. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol 2005;173:401–4.
35. Mengual L., Marin-Aguilera M., Ribal M.J. et al. Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guerin therapy. Eur Urol 2007; 52:752–9.
36. Pycha A., Mian C., Hofbauer J. et al. Does topical instillation therapy influence chromosomal aberrations in superficial bladder cancer? J Urol 1998; 159(1):265−9.
Рецензия
Для цитирования:
Матвеев В.Б., Карселадзе А.И., Казарян А.П., Хачатурян А.В., Камолов Б.Ш., Гигиадзе О.В., Калинин С.А. ВОЗМОЖНОСТИ ПРИМЕНЕНИЯ МЕТОДА ФЛУОРЕСЦЕНТНОЙ IN SITU ГИБРИДИЗАЦИИ (FISH) В ДИАГНОСТИКЕ РАКА МОЧЕВОГО ПУЗЫРЯ И ЕГО РЕЦИДИВОВ. Онкоурология. 2011;7(4):90-95. https://doi.org/10.17650/1726-9776-2011-7-4-90-95
For citation:
Matveev V.B., Karseladze A.I., Kazaryan A.P., Khachaturyan A.V., Kamolov B.Sh., Gigiadze O.V., Kalinin S.A. POSSIBILITIES OF USING THE FLUORESCENCE IN SITU HYBRIDIZATION TECHNIQUE IN THE DIAGNOSIS OF BLADDER CANCER AND ITS RECURRENCES. Cancer Urology. 2011;7(4):90-95. (In Russ.) https://doi.org/10.17650/1726-9776-2011-7-4-90-95
Просмотров:
1110
Послать статью по эл. почте 
